The current role of autologous stem transplantation in relapsed/refractory diffuse large B-cell lymphoma in the CAR-T therapy era

Sehn LH, Salles G. Diffuse Large B-Cell Lymphoma. N Engl J Med. 2021; 384:842-58.

Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018;378:1396-407.

Pfreundschuh M, Kuhnt E, Truper L, Osterborg A, Trneny, Shepherd L, et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 2011;12:1013-22.

Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab with CHOP alone in elderly patients with diffuse large-B lymphoma. N Engl J Med. 2002;346:235-42.

Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med. 1995;333:1540-5.

Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, et al. Salvage regimens with autogous transplantation for relapsed large-B cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-90.

Crump M, Kuruvilla J, Couban S, Macdonald DA, Kuret V, Kouroukis T, et al. Randomized comparison of gemcitabine dexathasone,cisplatin,versus dexathasone,cytabine,and cisplatin chemotherapy before autologous stem cell cell transplantation for relapsed and refractory aggressive lymphoma:NCIC-CTG LY.12. J Clini Oncol. 2014;32:3490-6.

Crump M, Neelapu SS, Farooq U, Van Den Neste E, Kuruvilla J, Westin J, et al. Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood. 2017;130:1800-8.

Schuster SJ, Bishop MR, Tam CC, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed Diffuse B-cell lymphoma. N Engl J Med. 2019;380:45-56.

Neelapu SS, Locke FL, Barlett NL, Lekakis JL, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Eng J Med. 2017;377:2531-44.

Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396;839-52.

Neelapu SS, Jacobson CA, Ghobadi A, Miklos DB, Lekakis LJ, Oluwole OO, et al. Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma. Blood. 2023;141:2307-15.

Locke L, Miklos DB, Jacobson CA, Perales MA, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large-B lymphoma. N Eng J Med. 2022;386:640-54.

Bishop M, Dickinson M, Purtill D, Baaaarba P, Santoro A, Hamad N, et al. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2022;386:629-39.

Abramson JS, Solomon CR, Arnason J, Johnson P, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675-83.

Westin JR, Locke FL, Dickinson, Ghobadi A, Elsawy M, van Meerten T, et al. Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma. Clin Cancer Res. 2023;29:1894-905.

Sehgal A, Hoda D, Riedell PA, Ghosh N, Hamadani M, Hildebrandt GC, et al. Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol. 2022;23:1066-77.

Nastoupil LJ, Jain MD, Feng L, Spiegel JY, Ghobadi A, Lin L, et al. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2020;38:3119-28.

Crombie JL, Nastoupil LJ, Andreadis C, Isufi I, Hunter B, Winter A, et al. Multicenter, Real-World Study in Patients with R/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood. 2023;142:suppl 104.

Bachier C, Godwin JE, Andreadis C, Paloma ML, Abramson JS, Sehgal AR, et al. Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL). J Clini Oncol. 2020;38;suppl 8037.

Ahmed D, Wesson W, Mustaq MU, Porter D, Nasta S, Brower, et al. Patient Characteristics and Outcomes of Outpatient Tisagenlecleucel Recipients for B Cell Non-Hodgkin Lymphoma. Transplant Cell Ther. 2023;29:449.e1-449.e7.

Shadman M, Pasquini M, Ahn kW, Chen Y, Turtle CJ, Hematti P, et al. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022;139:1330-9.

Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjane A, Iqbal M, et al. Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission. Blood Cancer J. 2024;14:108.

June CH, O'Connor RS, Kawalekar OU, Ghassemi S, Milone MC. CAR T cell immunotherapy for human cancer. Science. 2018:359;1361-5.

Schubert ML, Schmitt M, Wang L, Ramos CA, Jordan K, Tidow CM ,et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32:34-48.

Ghilardi G, Fraietta JA, Gerson JN, Van Deerlin VM, Morrisssette JD, Caponetti GC, et al. T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy. Nat Med. 2024;30:984-9.

Hamilton MP, Sugio T, Shuyu S, Bulterys PL, Liu CL, Kang S, et al. Risk of Second Tumors and T-Cell Lymphoma after CAR T-Cell Therapy. N Engl J Med. 2024;390:2047-60.

Verdun N, Marks P. Secondary Cancers after Chimeric Antigen Receptor T-Cell Therapy. N Engl J Med. 2024:390:584-6.